PI Publications
- 2025Third course of radical intent conformal radiation in patients with primary brain tumors. Clinical Oncology.
Jeeva M, Dasgupta A, Chatterjee A, Sahu A, Sridhar E, Moiyadi A, Chinnaswamy G, Gupta T
High-grade gliomas associated with neurofibromatosis type 1: analysis of imaging features and literature review. Polish Journal of RadiologyVijan A, Nair SM, Sahu A, Chopade P, Sridhar E, Jain A, Chatterjee A, Choudhari A, Prasad M, Chinnaswamy G, Singh V, Shetty P, Dasgupta A, Moiyadi A, Gupta T, Goda JS
- 2024Preliminary evaluation of FAPI-04-PET/CT for differentiating recurrence and post-treatment changes in high-grade gliomas. Exploration of Targeted Anti-tumor Therapy.5(6):1289-1296. PMID: 39759219.
Dev ID, Puranik AD, Rangarajan V, Patra S, Purandare N, Sahu A, Choudhary A, Bhattacharya K, Gupta T, Chatterjee A, Dasgupta A, Moiyadi A, Shetty P, Singh V, Sridhar E, Sahay A, Shah A, Ghosh S, Choudhury S, Shah S, Agrawal A
Multitarget Potential Drug Candidates for High-Grade Gliomas Identified by Multiple Reaction Monitoring Coupled with In Silico Drug Repurposing. OMICS: A Journal of Integrative Biology.28(2):59-75. PMID: 38320249.Verma A, Patel R, Mahale A, Thorat RV, Rath SL, Sridhar E, Moiyadi A, Srivastava S
- 2023Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. British Journal of Haematology. 200(4):429-439. PMID: 36323643.
Sengar M, Jain H, Shet T, Sridhar E, Gota V, Rangarajan V, Laskar SS, Alahari A, Thorat J, Agarwal A, Sharma N, Gupta H, Kannan S, Kumar S, Nayak L, Menon H, Gujral S, Bagal B
- 2022Long-term clinical outcomes and sequelae of therapy in early-stage orbital mucosa-associated lymphoid tissue lymphoma. Clinical Lymphoma Myeloma and Leukemia. 22(7):513-522. PMID: 35027338
Panda G, Kalra B, Rishi A, Khanna N, Kakoti S, Sridhar E, Shet T, Sengar M, Nayak L, Bagal B, Jain H, Laskar S, Goda J
- 2021Downregulation of ARID1B, a tumor-suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways. Human Molecular Genetics. 30(18):1721-1733. PMID: 33949667
Deogharkar A, Singh SV, Bharambe HS, Paul R, Moiyadi A, Goel A, Shetty P, Sridhar E, Gupta T, Jalali R, Goel N, Gadewal N, Muthukumar S, Shirsat NV
rognostic significance of 18F-FDG PET/CT parameters in IDH-1 wild-type GBM and correlation with molecular markers. Nuclear Medicine Communications. 11: 1233-1238. PMID: 34075008Dev ID, Puranik AD, Purandare NC, Gupta T, Sridhar E, Shetty P, Moiyadi A, Agrawal A, Shah S, Rangarajan V
Prospective longitudinal assessment of quality of life. and activities of daily living as patient-reported outcome measures in recurrent/progressive glioma treated with high-dose salvage re-irradiation. Clinical Oncology (R Coll Radiol). 33(3):e155-e165. PMID: 32917486Maitre P, Gupta T, Maitre M, Goda J, Krishnatry R, Chatterjee A, Sridhar E, Sahay A, Mokal S, Moiyadi A, Shetty P, Patil V, Jalali R
MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of group 4 medulloblastoma. Human Molecular Genetics. 30(24):2524-2525. PMID: 34274968.Paul R, Bapat P, Deogharkar A, Kazi S, Singh SKV, Gupta T, Jalali R, Sridhar E, Moiyadi A, Shetty P, Shirsat NV
Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomas. Journal of Neuroimaging. 31(6):1211-1218. PMID: 34388273.Puranik AD, Rangarajan V, Dev ID, Jain Y, Purandare NC, Sahu A, Choudhary A, Gupta T, Chatterjee A, Moiyadi A, Shetty P, Sridhar E, Sahay A, Patil VM, Shah S, Agrawal A